Answers are grounded in this paper and cite their sources.
Case report reveals vision loss after anti-VEGF injection in a woman with diabetic macular edema, suggesting potential risks.
This case report discusses bilateral vision loss 2 weeks after second bilateral intravitreal injection of the anti–vascular endothelial growth factor (VEGF) brolucizumab for diabetic macular edema in a woman in her 60s.
No takes yet. Share an insight, caveat, or question.
Ramtohul et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: